ClinConnect ClinConnect Logo
Search / Trial NCT04293458

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

Launched by LUCID DIAGNOSTICS, INC. · Feb 29, 2020

Trial Information

Current as of July 08, 2025

Completed

Keywords

ClinConnect Summary

This is a multicenter, single-arm study designed to assess the operating characteristics of the EsoGuard diagnostic assay performed on distal esophageal mucosal cells collected using the EsoCheck cell collection device, compared to the gold standard, for the screening of BE with and without dysplasia and for esophageal adenocarcinoma (EAC), in patients at high risk for BE and for whom a screening EGD is indicated according to ACG-established criteria.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Men aged 50 years old and older
  • 2. ≥5 years either of
  • GERD symptoms,
  • GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or,
  • any combination of treated and untreated periods, as long the cumulative total is at least 5 years
  • 3. No solid foods eaten for at least 2 hours prior to EsoCheck procedure
  • 4. One or more of the following risk factors:
  • 1. Caucasian race
  • 2. Current or past history of cigarette smoking
  • 3. BMI of at least 30 kg/m2
  • 4. First-degree relative with BE or EAC
  • -
  • Exclusion Criteria:
  • 1. History of prior EGD procedure
  • 2. Inability to provide written informed consent
  • 3. On anti-coagulant drug(s) that cannot be temporarily discontinued
  • 4. Known history of esophageal varices or esophageal stricture
  • 5. Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
  • 6. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
  • 7. Oropharyngeal tumor
  • 8. History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
  • 9. History of myocardial infarction or cerebrovascular accident within past 6 months
  • 10. History of esophageal motility disorder
  • 11. Currently implanted Linx device

About Lucid Diagnostics, Inc.

Lucid Diagnostics, Inc. is a pioneering medical technology company focused on transforming the early detection and monitoring of gastrointestinal diseases. With a commitment to advancing patient care, Lucid develops innovative diagnostic solutions that leverage cutting-edge technology and evidence-based research. Their flagship product, a non-invasive test for dysplasia and esophageal cancer, exemplifies the company’s dedication to improving clinical outcomes and enhancing patient quality of life. Through ongoing clinical trials and partnerships, Lucid Diagnostics aims to expand its portfolio of diagnostic tools and contribute to the advancement of precision medicine in gastroenterology.

Locations

Orange, California, United States

Englewood, Colorado, United States

Jacksonville, Florida, United States

Naples, Florida, United States

Palm Harbor, Florida, United States

Macon, Georgia, United States

Idaho Falls, Idaho, United States

Rockford, Illinois, United States

New Orleans, Louisiana, United States

Shreveport, Louisiana, United States

Wyoming, Michigan, United States

Flowood, Mississippi, United States

Omaha, Nebraska, United States

New York, New York, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Oklahoma City, Oklahoma, United States

Philadelphia, Pennsylvania, United States

Providence, Rhode Island, United States

Greenville, South Carolina, United States

Knoxville, Tennessee, United States

Nashville, Tennessee, United States

Houston, Texas, United States

Salt Lake City, Utah, United States

Richmond, Virginia, United States

Bellevue, Washington, United States

Madrid, , Spain

Valladolid, , Spain

Zaragoza, , Spain

Patients applied

0 patients applied

Trial Officials

Michelle McDermott

Study Director

Lucid Diagnostics

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials